We validated reduced expression of EZH2 in AML cells compared to control CD34-selected cells in one public dataset and confirmed that EZH2 can be inhibited by miR-101-3p which was increased in MSC-derived exosomes in patients with AML. Here, EZH2 is linked to acute myeloid leukemia.